Search

Your search keyword '"Lopez-Pedrera, Chary"' showing total 157 results
Start Over Author "Lopez-Pedrera, Chary"
157 results on '"Lopez-Pedrera, Chary"'

1. Personalized cardiovascular risk assessment in Rheumatoid Arthritis patients using circulating molecular profiles and their modulation by TNFi, IL6Ri, and JAKinibs

Author

Muñoz-Barrera, Laura, Perez-Sanchez, Carlos, Ortega-Castro, Rafaela, Corrales, Sagrario, Luque-Tevar, Maria, Cerdó, Tomás, Sanchez-Pareja, Ismael, Font, Pilar, Lopez-Mejías, Raquel, Calvo, Jerusalem, Abalos-Aguilera, M.Carmen, Ruiz-Vilchez, Desiree, Segui, Pedro, Merlo, Christian, Perez-Venegas, José, Ruiz Montesino, Ma Dolores, Rodriguez- Escalera, Carlos, Barco, Carmen Romero, Fernandez-Nebro, Antonio, Vazque, Natalia Mena, Marenco, Jose Luis, Montañes, Julia Uceda, Godoy-Navarrete, Javier, Cabezas-Lucena, Alba Ma, Estevez, Eduardo Collantes, Aguirre, Ma Angeles, González-Gay, Miguel A., Barbarroja, Nuria, Escudero-Contreras, Alejandro, and Lopez-Pedrera, Chary

Published
2024
Full Text
View/download PDF

4. Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study

Author

Pons-Estel, Guillermo, Giannakopoulos, Bill, Krilis, Steve, de Jesus, Guilherme, Levy, Roger, Signorelli, Flavio, Andrade, Danieli, Balbi, Gustavo, Clarke, Ann E., Skeith, Leslie, Fortin, Paul R., Ji, Lanlan, Zhang, Zhouli, Yang, Chengde, Shi, Hui, Zuily, Stephane, Wahl, Denis, Tektonidou, Maria G., Nalli, Cecilia, Andreoli, Laura, Tincani, Angela, Chighizola, Cecilia B., Gerosa, Maria, Meroni, Pierluigi, Pengo, Vittorio, Cheng, Chunyan, Pazzola, Giulia, Sciascia, Savino, Foddai, Silvia, Radin, Massimo, Davis, Stacy, Amengual, Olga, Atsumi, Tatsuya, Uthman, Imad, Limper, Maarten, Groot, Philip de, Ruiz—Irastorza, Guillermo, Ugarte, Amaia, Rodriguez-Pinto, Ignasi, Cervera, Ricard, Pardos-Gea, Jose, Rodriguez Almaraz, Esther, Cuadrado, Maria Jose, Aguirre Zamorano, Maria Angeles, Lopez-Pedrera, Chary, Artim-Esen, Bahar, Inanc, Murat, Bertolaccini, Maria Laura, Cohen, Hannah, Efthymiou, Maria, Khamashta, Munther, Mackie, Ian, Sanna, Giovanni, Knight, Jason, Zuo, Yu, Petri, Michelle, Leaf, Rebecca K., Roubey, Robert, Ortel, Thomas, Gonzalez, Emilio, Willis, Rohan, Kello, Nina, Belmont, Michael, Levine, Steven, Rand, Jacob, Barbhaiya, Medha, Erkan, Doruk, Salmon, Jane, Lockshin, Michael, Duarte Garcia, Ali A., Branch, D. Ware, Gkrouzman, Elena, Ruiz-Irastorza, Guillermo, Belmont, H. Michael, Rodriguez-Almaraz, Esther, Petri, Michelle A., and Knight, Jason S.

Published
2023
Full Text
View/download PDF

5. Pathogenic mechanisms involving the interplay between adipose tissue and auto-antibodies in rheumatoid arthritis

Author

Arias-de la Rosa, Iván, Escudero-Contreras, Alejandro, Ruiz-Ponce, Miriam, Cuesta-López, Laura, Román-Rodríguez, Cristóbal, Pérez-Sánchez, Carlos, Ruiz-Limón, Patricia, Ruiz, Rocío Guzman, Leiva-Cepas, Fernando, Alcaide, Juan, Segui, Pedro, Plasencia, Chamaida, Martinez-Feito, Ana, Font, Pilar, Ábalos, María C., Ortega, Rafaela, Malagón, María M., Tinahones, Francisco J., Collantes-Estévez, Eduardo, López-Pedrera, Chary, and Barbarroja, Nuria

Published
2022
Full Text
View/download PDF

6. Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry.

Author

Balbi, Gustavo G M, Ahmadzadeh, Yasaman, Tektonidou, Maria G, Pengo, Vittorio, Sciascia, Savino, Ugarte, Amaia, Belmont, H Michael, Lopez-Pedrera, Chary, Fortin, Paul R, Wahl, Denis, Gerosa, Maria, Jesús, Guilherme R de, Ji, Lanlan, Atsumi, Tatsuya, Efthymiou, Maria, Branch, D Ware, Nalli, Cecilia, Almaraz, Esther Rodriguez, Petri, Michelle, and Cervera, Ricard

Subjects
THROMBOSIS, CLINICAL pathology, HYPERTENSION, CARDIOVASCULAR diseases risk factors, AUTOANTIBODIES, REPORTING of diseases, CONFIDENCE intervals, ADRENOCORTICAL hormones, ANTIPHOSPHOLIPID syndrome, CROSS-sectional method, AUTOIMMUNE diseases, ANTICOAGULANTS, HYPERLIPIDEMIA, SYMPTOMS, DESCRIPTIVE statistics, ODDS ratio
Abstract

Objectives Our primary objective was to quantify damage burden measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in aPL-positive patients with or without a history of thrombosis in an international cohort (the APS ACTION cohort). Secondly, we aimed to identify clinical and laboratory characteristics associated with damage in aPL-positive patients. Methods In this cross-sectional study, we analysed the baseline damage in aPL-positive patients with or without APS classification. We excluded patients with other autoimmune diseases. We analysed the demographic, clinical and laboratory characteristics based on two subgroups: (i) thrombotic APS patients with high vs low damage; and (ii) non-thrombotic aPL-positive patients with vs without damage. Results Of the 826 aPL-positive patients included in the registry as of April 2020, 586 with no other systemic autoimmune diseases were included in the analysis (412 thrombotic and 174 non-thrombotic). In the thrombotic group, hyperlipidaemia (odds ratio [OR] 1.82; 95% CI 1.05, 3.15; adjusted P  = 0.032), obesity (OR 2.14; 95% CI 1.23, 3.71; adjusted P  = 0.007), aβ2GPI high titres (OR 2.33; 95% CI 1.36, 4.02; adjusted P  = 0.002) and corticosteroid use (ever) (OR 3.73; 95% CI 1.80, 7.75; adjusted P  < 0.001) were independently associated with high damage at baseline. In the non-thrombotic group, hypertension (OR 4.55; 95% CI 1.82, 11.35; adjusted P  = 0.001) and hyperlipidaemia (OR 4.32; 95% CI 1.37, 13.65; adjusted P  = 0.013) were independent predictors of damage at baseline; conversely, single aPL positivity was inversely correlated with damage (OR 0.24; 95% CI 0.075, 0.77; adjusted P  = 0.016). Conclusions DIAPS indicates substantial damage in aPL-positive patients in the APS ACTION cohort. Selected traditional cardiovascular risk factors, steroids use and specific aPL profiles may help to identify patients more prone to present with a higher damage burden. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation

Author

Ruiz-Limón, Patricia, Ortega, Rafaela, Arias de la Rosa, Ivan, Abalos-Aguilera, Maria del Carmen, Perez- Sanchez, Carlos, Jimenez- Gomez, Yolanda, Peralbo-Santaella, Esther, Font, Pilar, Ruiz-Vilches, Desiree, Ferrin, Gustavo, Collantes-Estevez, Eduardo, Escudero-Contreras, Alejandro, López- Pedrera, Chary, and Barbarroja, Nuria

Published
2017
Full Text
View/download PDF

8. Enhanced NETosis generation in radiographic axial spondyloarthritis: utility as biomarker for disease activity and anti-TNF-α therapy effectiveness

Author

Ruiz-Limon, Patricia, Ladehesa-Pineda, Maria Lourdes, Castro-Villegas, Maria del Carmen, Abalos-Aguilera, Maria del Carmen, Lopez-Medina, Clementina, Lopez-Pedrera, Chary, Barbarroja, Nuria, Espejo-Peralbo, Daniel, Gonzalez-Reyes, Jose Antonio, Villalba, Jose Manuel, Perez-Sanchez, Carlos, Escudero-Contreras, Alejandro, Collantes-Estevez, Eduardo, Font-Ugalde, Pilar, and Jimenez-Gomez, Yolanda

Published
2020
Full Text
View/download PDF

9. Preclinical characterization of pharmacological NAD + boosting as a promising therapeutic approach in Rheumatoid Arthritis

Author

Perez‐Sanchez, Carlos, primary, Escudero‐Contreras, Alejandro, additional, Cerdó, Tomás, additional, Sánchez‐Mendoza, Luz Marina, additional, Llamas‐Urbano, Adrián, additional, Arias‐de la Rosa, Iván, additional, Pérez‐Rodriguez, Miguel, additional, Muñoz‐Barrera, Laura, additional, Abalos‐Aguilera, María del Carmen, additional, Barbarroja, Nuria, additional, Calvo, Jerusalem, additional, Ortega‐Castro, Rafaela, additional, Ruiz‐Vilches, Desiree, additional, Moreno, Juan Antonio, additional, Burón, María Isabel, additional, González‐Reyes, José Antonio, additional, Collantes‐Estevez, Eduardo, additional, Lopez‐Pedrera, Chary, additional, and Villalba, José Manuel, additional

Published
2023
Full Text
View/download PDF

10. The thrombus proteome in stroke reveals a key role of the innate immune system and new insights associated with its aetiology, severity and prognosis

Author

Lopez-Pedrera, Chary, primary, Oteros, Rafael, additional, Ibáñez-Costa, Alejandro, additional, Luque-Tévar, María, additional, Muñoz-Barrera, Laura, additional, Barbarroja, Nuria, additional, Chicano-Gálvez, Eduardo, additional, Marta-Enguita, Juan, additional, Orbe, Josune, additional, Velasco, Francisco, additional, and Perez-Sánchez, Carlos, additional

Published
2023
Full Text
View/download PDF

12. Preclinical Characterization of Pharmacologic NAD+ Boosting as a Promising Therapeutic Approach in Rheumatoid Arthritis.

Author

Perez‐Sanchez, Carlos, Escudero‐Contreras, Alejandro, Cerdó, Tomás, Sánchez‐Mendoza, Luz Marina, Llamas‐Urbano, Adrián, la Rosa, Iván Arias‐de, Pérez‐Rodriguez, Miguel, Muñoz‐Barrera, Laura, del Carmen Abalos‐Aguilera, María, Barbarroja, Nuria, Calvo, Jerusalem, Ortega‐Castro, Rafaela, Ruiz‐Vilchez, Desiree, Moreno, Juan Antonio, Burón, María Isabel, González‐Reyes, José Antonio, Collantes‐Estevez, Eduardo, Lopez‐Pedrera, Chary, and Villalba, José Manuel

Subjects
CLINICAL drug trials, ANTI-inflammatory agents, TREATMENT effectiveness, GENE expression, RHEUMATOID arthritis, DRUG development, CLUSTER analysis (Statistics), PATIENT safety
Abstract

Objective: We analyzed NAD+ metabolism in patients with rheumatoid arthritis (RA), its association with disease activity and clinical outcomes of RA, and the therapeutic potential of pharmacologic NAD+ boosting. Methods: Our study included 253 participants. In the first cohort, comprising 153 RA patients and 56 healthy donors, we assessed NAD+ levels and NAD+‐related gene pathways. We analyzed 92 inflammatory molecules by proximity extension assay. In the second cohort, comprising 44 RA patients starting anti–tumor necrosis factor (anti‐TNF) drugs, we evaluated changes in NAD+ levels and their association with clinical response after 3 months. Mechanistic studies were performed ex vivo on peripheral blood mononuclear cells (PBMCs) from patients with RA to test the beneficial effects of NAD+ boosters, such as nicotinamide and nicotinamide riboside. Results: Reduced NAD+ levels were found in RA samples, in line with altered activity and expression of genes involved in NAD+ consumption (sirtuins, poly[ADP‐ribose] polymerase, CD38), transport (connexin 43), and biosynthesis (NAMPT, NMNATs). Unsupervised clustering analysis identified a group of RA patients with the highest inflammatory profile, the lowest NAD+ levels, and the highest disease activity (as shown by the Disease Activity Score in 28 joints). NAD+ levels were modulated by anti‐TNF therapy in parallel with the clinical response. In vitro studies using PBMCs from RA patients showed that nicotinamide riboside and nicotinamide increased NAD+ levels via NAMPT and NMNAT and reduced their prooxidative, proapoptotic, and proinflammatory status. Conclusion: RA patients display altered NAD+ metabolism, directly linked to their inflammatory and disease activity status, which was reverted by anti‐TNF therapy. The preclinical beneficial effects of NAD+ boosters, as shown in leukocytes from RA patients, along with their proven clinical safety, might pave the way for the development of clinical trials using these compounds. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Thrombosis Recurrence and Major Bleeding in Non-Anticoagulated Thrombotic Antiphospholipid Syndrome Patients: Prospective Study from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (Aps Action) Clinical Database and Repository (“Registry”)

Author

Yelnik, Cécile Marie, primary, Erton, Zeynep Belce, additional, Drumez, Elodie, additional, Cheildze, Dachi, additional, Andrade, Danieli Castro Oliveira, additional, Clarke, Ann E., additional, Tektonidou, Maria, additional, Sciascia, Savino, additional, Pardos-Gea, Jose, additional, Pengo, Vittorio, additional, Ruiz-Irastorza, Guillermo, additional, Belmont, Michael H., additional, Lopez Pedrera, Chary, additional, Fortin, Paul R., additional, Wahl, Denis, additional, Gerosa, Maria, additional, Kello, Nina, additional, Signorelli, Flavio, additional, Atsumi, Tatsuya, additional, Ji, Lanlan, additional, Cohen, Hannah, additional, Branch, D. Ware, additional, Nalli, Cecilia, additional, Rodriguez-Almaraz, Esther, additional, Petri, Michelle, additional, Cervera, Ricard, additional, Shi, Hui, additional, Zuo, Yu, additional, Artim-Esen, Bahar, additional, Pons-Estel, Guillermo, additional, Willis, Rohan, additional, Barber, Megan, additional, Skieth, Leslie, additional, Bertolaccini, Maria Laura, additional, Roubey, Robert, additional, and Erkan, Doruk, additional

Published
2023
Full Text
View/download PDF

16. Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

Author

Erton, Zeynep B, primary, K Leaf, Rebecca, additional, de Andrade, Danieli, additional, Clarke, Ann E, additional, Tektonidou, Maria G, additional, Pengo, Vittorio, additional, Sciascia, Savino, additional, Ugarte, Amaia, additional, Belmont, H. Michael, additional, Gerosa, Maria, additional, Fortin, Paul R, additional, Lopez-Pedrera, Chary, additional, Atsumi, Tatsuya, additional, Zhang, Zhouli, additional, Cohen, Hannah, additional, Ramires de Jesús, Guilherme, additional, Branch, David W, additional, Wahl, Denis, additional, Andreoli, Laura, additional, Rodriguez-Almaraz, Esther, additional, Petri, Michelle, additional, Barilaro, Giuseppe, additional, Zuo, Yu, additional, Artim-Esen, Bahar, additional, Willis, Rohan, additional, Quintana, Rosana, additional, Vendramini, Margarete BG, additional, Barber, Megan W, additional, Bertolaccini, Maria L, additional, Roubey, Robert, additional, and Erkan, Doruk, additional

Published
2022
Full Text
View/download PDF

18. Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment

Author

Perez-Sanchez, Carlos, Ruiz-Limon, Patricia, Aguirre, Maria Angeles, Bertolaccini, Maria Laura, Khamashta, Munther A., Rodriguez-Ariza, Antonio, Segui, Pedro, Collantes-Estevez, Eduardo, Barbarroja, Nuria, Khraiwesh, Husam, Gonzalez-Reyes, Jose Antonio, Villalba, Jose Manuel, Velasco, Francisco, Cuadrado, Maria Jose, and Lopez-Pedrera, Chary

Published
2012
Full Text
View/download PDF

19. A new molecular classification to drive precision treatment strategies in primary Sjögren’s syndrome

Author

Soret, Perrine, Le Dantec, Christelle, Desvaux, Emiko, Foulquier, Nathan, Chassagnol, Bastien, Hubert, Sandra, Christophe, Jamin, Barturen, Guillermo, Desachy, Guillaume, Devauchelle-Pensec, Valérie, Boudjeniba, Cheïma, Cornec, Divi, Saraux, Alain, Jousse-Joulin, Sandrine, Barbarroja, Nuria, Rodríguez-Pintó, Ignasi, de Langhe, Ellen, Beretta, Lorenzo, Chizzolini, Carlo, Kovács, László, Witte, Torsten, Bettacchioli, Eléonore, Buttgereit, Anne, Makowska, Zuzanna, Lesche, Ralf, Borghi, Maria Orietta, Martin, Javier, Courtade-Gaiani, Sophie, Xuereb, Laura, Guedj, Mickaël, Moingeon, Philippe, Alarcón-Riquelme, Marta, Laigle, Laurence, Pers, Jacques-Olivier, Vigone, Barbara, Lauwerys, Bernard, Maudoux, Anne-Lise, Vasconcelos, Carlos, Tavares, Ana, Faria, Raquel, Brandão, Mariana, Campar, Ana, Marinho, António, Farinha, Fátima, Almeida, Isabel, Gonzalez-Gay Mantecón, Miguel Angel, Blanco Alonso, Ricardo, Corrales Martínez, Alfonso, Cervera, Ricard, Espinosa, Gerard, Lories, Rik, Hunzelmann, Nicolas, Belz, Doreen, Baerlecken, Niklas, Stummvoll, Georg, Zauner, Michael, Lehner, Michaela, Collantes, Eduardo, Ortega-Castro, Rafaela, Aguirre-Zamorano, Ma Angeles, Escudero-Contreras, Alejandro, Castro-Villegas, Ma Carmen, Jiménez Gómez, Yolanda, Ortego, Norberto, Fernández Roldán, María Concepción, Raya, Enrique, Jiménez Moleón, Inmaculada, de Ramon, Enrique, Díaz Quintero, Isabel, Meroni, Pier Luigi, Gerosa, Maria, Schioppo, Tommaso, Artusi, Carolina, Zuber, Aleksandra, Wynar, Donatienne, Balog, Attila, Deák, Magdolna, Bocskai, Márta, Dulic, Sonja, Kádár, Gabriella, Hiepe, Falk, Thiel, Silvia, Rodriguez Maresca, Manuel, López-Berrio, Antonio, Aguilar-Quesada, Rocío, Navarro-Linares, Héctor, Ioannou, Yiannis, Chamberlain, Chris, Marovac, Jacqueline, Alarcón Riquelme, Marta, Gomes Anjos, Tania, Marañón, Concepción, Le Lann, Lucas, Simon, Quentin, Rouvière, Bénédicte, Varela, Nieves, Muchmore, Brian, Dufour, Aleksandra, Alvarez, Montserrat, Cremer, Jonathan, Lopez-Pedrera, Chary, Gerl, Velia, Khodadadi, Laleh, Cheng, Qingyu, de Groof, Aurélie, Ducreux, Julie, Trombetta, Elena, Li, Tianlu, Alvarez-Errico, Damiana, Kniesch, Katja, Azevedo, Nancy, Neves, Esmeralda, Rao, Sambasiva, Jouve, Pierre-Emmanuel, Institut de Recherches Internationales Servier [Suresnes] (IRIS), Lymphocytes B, Autoimmunité et Immunothérapies (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-LabEX IGO Immunothérapie Grand Ouest, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Centre for Genomics and Oncological Reearch (GENYO), CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Instituto Maimonides de Investigación Biomédica de Cordoba (IMIBIC), Universidad de Córdoba = University of Córdoba [Córdoba]-Hospital Universitario Reina Sofía, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Maggiore Hospital, IRCCS Foundation, Milano, Department of Pathology and Immunology [Geneva, Switzerland], Université de Genève = University of Geneva (UNIGE), University of Szeged [Szeged], Clinic for Immunology and Rhematology, Hannover Medical School, Hanover, Germany, Hôpital Morvan - CHRU de Brest (CHU - BREST ), Pharmaceuticals Division Bayer Pharma Aktiengesellschaft, Università degli Studi di Milano = University of Milan (UNIMI), Instituto de Parasitología y Biomedicina 'López-Neyra' (IPBLN), Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Granada = University of Granada (UGR), and Michel, Geneviève

Subjects
MESH: Databases, Protein, MESH: Inflammation, [SDV.IMM] Life Sciences [q-bio]/Immunology, MESH: Flow Cytometry, MESH: Cross-Sectional Studies, MESH: DNA Methylation, MESH: Computer Simulation, cell cycle, chronic lymphocytic leukemia, liquid chromatography-tandem mass spectrometry, splicing, MESH: Autoantibodies, MESH: Interferons, MESH: RNA-Seq, MESH: Cohort Studies, MESH: Databases, Genetic, MESH: Cytokines, MESH: Humans, MESH: Middle Aged, MESH: Polymorphism, Single Nucleotide, MESH: Transcriptome, MESH: Adult, MESH: Chemokines, MESH: Male, MESH: Proteome, MESH: Sjogren's Syndrome, MESH: Genome-Wide Association Study, MESH: Biomarkers, MESH: Multigene Family, [SDV.IMM]Life Sciences [q-bio]/Immunology, MESH: Female, MESH: Computational Biology
Abstract

International audience; Abstract There is currently no approved treatment for primary Sjögren’s syndrome, a disease that primarily affects adult women. The difficulty in developing effective therapies is -in part- because of the heterogeneity in the clinical manifestation and pathophysiology of the disease. Finding common molecular signatures among patient subgroups could improve our understanding of disease etiology, and facilitate the development of targeted therapeutics. Here, we report, in a cross-sectional cohort, a molecular classification scheme for Sjögren’s syndrome patients based on the multi-omic profiling of whole blood samples from a European cohort of over 300 patients, and a similar number of age and gender-matched healthy volunteers. Using transcriptomic, genomic, epigenetic, cytokine expression and flow cytometry data, combined with clinical parameters, we identify four groups of patients with distinct patterns of immune dysregulation. The biomarkers we identify can be used by machine learning classifiers to sort future patients into subgroups, allowing the re-evaluation of response to treatments in clinical trials.

Published
2021

21. Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy

Author

Ibáñez-Costa, Alejandro, primary, Perez-Sanchez, Carlos, additional, Patiño-Trives, Alejandra María, additional, Luque-Tevar, Maria, additional, Font, Pilar, additional, Arias de la Rosa, Ivan, additional, Roman-Rodriguez, Cristobal, additional, Abalos-Aguilera, Mª Carmen, additional, Conde, Carmen, additional, Gonzalez, Antonio, additional, Pedraza-Arevalo, Sergio, additional, del Rio-Moreno, Mercedes, additional, Blazquez-Encinas, Ricardo, additional, Segui, Pedro, additional, Calvo, Jerusalem, additional, Ortega Castro, Rafaela, additional, Escudero-Contreras, Alejandro, additional, Barbarroja, Nuria, additional, Aguirre, Mª Angeles, additional, Castaño, Justo P, additional, Luque, Raul M, additional, Collantes-Estevez, Eduardo, additional, and Lopez-Pedrera, Chary, additional

Published
2021
Full Text
View/download PDF

22. Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment

Author

Ruiz-Limon, Patricia, Barbarroja, Nuria, Perez-Sanchez, Carlos, Aguirre, Maria Angeles, Bertolaccini, Maria Laura, Khamashta, Munther A, Rodriguez-Ariza, Antonio, Almadén, Yolanda, Segui, Pedro, Khraiwesh, Husam, Gonzalez-Reyes, Jose Antonio, Villalba, Jose Manuel, Collantes-Estevez, Eduardo, Cuadrado, Maria Jose, and Lopez-Pedrera, Chary

Published
2015
Full Text
View/download PDF

23. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus

Author

Perez-Sanchez, Carlos, Barbarroja, Nuria, Messineo, Sebastiano, Ruiz-Limon, Patricia, Rodriguez-Ariza, Antonio, Jimenez-Gomez, Yolanda, Khamashta, Munther A, Collantes-Estevez, Eduardo, Cuadrado, M Jose, Aguirre, M Angeles, and Lopez-Pedrera, Chary

Published
2015
Full Text
View/download PDF

25. Potential Role and Impact of Peripheral Blood Mononuclear Cells in Radiographic Axial Spondyloarthritis-Associated Endothelial Dysfunction

Author

Ruiz-Limon, Patricia, primary, Ladehesa-Pineda, Maria L., additional, Lopez-Medina, Clementina, additional, Lopez-Pedrera, Chary, additional, Abalos-Aguilera, Maria C., additional, Barbarroja, Nuria, additional, Arias-Quiros, Isabel, additional, Perez-Sanchez, Carlos, additional, Arias-de la Rosa, Ivan, additional, Ortega-Castro, Rafaela, additional, Escudero-Contreras, Alejandro, additional, Collantes-Estevez, Eduardo, additional, and Jimenez-Gomez, Yolanda, additional

Published
2021
Full Text
View/download PDF

26. Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository

Author

Lopes, Erivelton de Azevedo Moreira Balbi, Gustavo Guimaraes and Tektonidou, Maria G. Pengo, Vittorio Sciascia, Savino and Ugarte, Amaia Belmont, H. Michael Gerosa, Maria Fortin, Paul R. Lopez-Pedrera, Chary Ji, Lanlan Cohen, Hannah de Jesus, Guilherme Ramires Branch, D. Ware Nalli, Cecilia and Petri, Michelle Rodriguez, Esther Kello, Nina Rios-Garces, Roberto Knight, Jason S. Atsumi, Tatsuya Willis, Rohan and Bertolaccini, Maria Laura Erkan, Doruk Andrade, Danieli APS ACTION

Subjects
immune system diseases
Abstract

Background Antiphospholipid syndrome (APS) is characterized by episodes of thrombosis, obstetric morbidity or both, associated with persistently positive antiphospholipid antibodies (aPL). Studying the profile of a rare disease in an admixed population is important as it can provide new insights for understanding an autoimmune disease. In this sense of miscegenation, Brazil is characterized by one of the most heterogeneous populations in the world, which is the result of five centuries of interethnic crosses of people from three continents. The objective of this study was to compare the clinical and laboratory characteristics of Brazilian vs. non-Brazilian primary antiphospholipid syndrome (PAPS) patients. Methods We classified PAPS patients into 2 groups: Brazilian PAPS patients (BPAPS) and PAPS patients from other countries (non-BPAPS). They were compared regarding demographic characteristics, criteria and non-criteria APS manifestations, antiphospholipid antibody (aPL) profile, and the adjusted Global Antiphospholipid Syndrome Score (aGAPSS). Results We included 415 PAPS patients (88 [21%] BPAPS and 327 [79%] non-BPAPS). Brazilian patients were significantly younger, more frequently female, sedentary, obese, non-white, and had a higher frequency of livedo (25% vs. 10%, p < 0.001), cognitive dysfunction (21% vs. 8%, p = 0.001) and seizures (16% vs. 7%, p = 0.007), and a lower frequency of thrombocytopenia (9% vs. 18%, p = 0.037). Additionally, they were more frequently positive for lupus anticoagulant (87.5% vs. 74.6%, p = 0.01), and less frequently positive to anticardiolipin (46.6% vs. 73.7%, p < 0.001) and anti-ss2-glycoprotein-I (13.6% vs. 62.7%, p < 0.001) antibodies. Triple aPL positivity was also less frequent (8% vs. 41.6%, p < 0.001) in Brazilian patients. Median aGAPSS was lower in the Brazilian group (8 vs. 10, p < 0.0001). In the multivariate analysis, BPAPS patients still presented more frequently with livedo, cognitive dysfunction and sedentary lifestyle, and less frequently with thrombocytopenia and triple positivity to aPL. They were also less often white. Conclusions Our study suggests a specific profile of PAPS in Brazil with higher frequency of selected non-criteria manifestations and lupus anticoagulant positivity. Lupus anticoagulant (not triple positivity) was the major aPL predictor of a classification criteria event.

Published
2021

28. Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis

Author

Luque-Tévar, Maria, primary, Perez-Sanchez, Carlos, additional, Patiño-Trives, Alejandra Mª, additional, Barbarroja, Nuria, additional, Arias de la Rosa, Ivan, additional, Abalos-Aguilera, Mª Carmen, additional, Marin-Sanz, Juan Antonio, additional, Ruiz-Vilchez, Desiree, additional, Ortega-Castro, Rafaela, additional, Font, Pilar, additional, Lopez-Medina, Clementina, additional, Romero-Gomez, Montserrat, additional, Rodriguez-Escalera, Carlos, additional, Perez-Venegas, Jose, additional, Ruiz-Montesinos, Mª Dolores, additional, Dominguez, Carmen, additional, Romero-Barco, Carmen, additional, Fernandez-Nebro, Antonio, additional, Mena-Vazquez, Natalia, additional, Marenco, Jose Luis, additional, Uceda-Montañez, Julia, additional, Toledo-Coello, Mª Dolores, additional, Aguirre, M. Angeles, additional, Escudero-Contreras, Alejandro, additional, Collantes-Estevez, Eduardo, additional, and Lopez-Pedrera, Chary, additional

Published
2021
Full Text
View/download PDF

29. Effects of Biological Therapies on Molecular Features of Rheumatoid Arthritis

Author

Lopez-Pedrera, Chary, Barbarroja, Nuria, Patiño-Trives, Alejandra M., Luque-Tévar, Maria, Collantes-Estevez, Eduardo, Escudero-Contreras, Alejandro, Pérez-Sánchez, Carlos, [Lopez-Pedrera,C, Barbarroja,N, Patiño-Trives,AM, Luque-Tévar,M, Collantes-Estevez,E, Escudero-Contreras,A, Pérez-Sánchez,C] Rheumatology Service, Reina Sofia Hospital, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), University of Cordoba,Córdoba, Spain., and This study was supported by grants from the Instituto de Salud Carlos III (ref. PI18/00837), co-founded by the Fondo Europeo de Desarrollo Regional de la Unión Europea ‘Una manera de hacer Europa’, Spain, the Spanish Inflammatory and Rheumatic Diseases Network (RIER), Instituto de Salud Carlos III (RD16/0012/0015) and the Servicio Andaluz de Salud (PI-0285-2017). C.L-P was supported by a contract from the Spanish Junta de Andalucía (‘Nicolas Monardes’ Program).

Subjects
Inflammation, Phenomena and Processes::Immune System Phenomena::Immunity::Autoimmunity [Medical Subject Headings], Genome, Inflamación, NETosis, Autoimmunity, Estrés oxidativo, Autoinmunidad, Artritis reumatoide, Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::RNA::RNA, Antisense::MicroRNAs [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Biological Therapy [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Diseases::Musculoskeletal Diseases::Rheumatic Diseases::Arthritis, Rheumatoid [Medical Subject Headings], Antirreumáticos, Oxidative stress, Epigenetic and pos-transcriptional mechanisms, Organisms::Eukaryota::Animals [Medical Subject Headings], bDMARDs, Rheumatoid arthritis, Phenomena and Processes::Metabolic Phenomena::Metabolism::Oxidative Stress [Medical Subject Headings], Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation [Medical Subject Headings], Genoma
Abstract

Rheumatoid arthritis (RA) is an autoimmune and chronic inflammatory disease primarily affecting the joints, and closely related to specific autoantibodies that mostly target modified self-epitopes. Relevant findings in the field of RA pathogenesis have been described. In particular, new insights come from studies on synovial fibroblasts and cells belonging to the innate and adaptive immune system, which documented the aberrant production of inflammatory mediators, oxidative stress and NETosis, along with relevant alterations of the genome and on the regulatory epigenetic mechanisms. In recent years, the advances in the understanding of RA pathogenesis by identifying key cells and cytokines allowed the development of new targeted disease-modifying antirheumatic drugs (DMARDs). These drugs considerably improved treatment outcomes for the majority of patients. Moreover, numerous studies demonstrated that the pharmacological therapy with biologic DMARDs (bDMARDs) promotes, in parallel to their clinical efficacy, significant improvement in all these altered molecular mechanisms. Thus, continuous updating of the knowledge of molecular processes associated with the pathogenesis of RA, and on the specific effects of bDMARDs in the correction of their dysregulation, are essential in the early and correct approach to the treatment of this complex autoimmune disorder. The present review details basic mechanisms related to the physiopathology of RA, along with the core mechanisms of response to bDMARDs. Yes

Published
2020

30. Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository

Author

Gkrouzman, Elena, Sevim, Ecem, Finik, Jackie, Andrade, Danieli, Pengo, Vittorio, Sciascia, Savino, Tektonidou, Maria G, Ugarte, Amaia, Chighizola, Cecilia B, Belmont, H Michael, Lopez-Pedrera, Chary, Ji, Lanlan, Fortin, Paul, Efthymiou, Maria, de Jesus, Guilherme Ramires, Branch, D Ware, Nalli, Cecilia, Petri, Michelle, Rodriguez, Esther, Cervera, Ricard, Knight, Jason S, Atsumi, Tatsuya, Willis, Rohan, Bertolaccini, Maria Laura, Cohen, Hannah, Rand, Jacob, Erkan, Doruk, and APS ACTION+

Subjects
medicine.medical_specialty, Immunology, anticardiolipin antibodies, Anticardiolipin antibodies, Antiphospholipid antibodies, Antiphospholipid syndrome, 030204 cardiovascular system & hematology, Odds, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, immune system diseases, Median follow-up, Antibody Profile, Internal medicine, medicine, Immunology and Allergy, Humans, Prospective Studies, neoplasms, 030203 arthritis & rheumatology, Lupus anticoagulant, business.industry, antiphospholipid antibodies, Odds ratio, medicine.disease, Antiphospholipid Syndrome, Confidence interval, beta 2-Glycoprotein I, Cohort, Antibodies, Antiphospholipid, business
Abstract

ObjectiveThe APS ACTION Registry studies long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients. Our primary objective was to determine whether clinically meaningful aPL profiles at baseline remain stable over time. Our secondary objectives were to determine (1) whether baseline characteristics differ between patients with stable and unstable aPL profiles, and (2) predictors of unstable aPL profiles over time.MethodsA clinically meaningful aPL profile was defined as positive lupus anticoagulant (LAC) test and/or anticardiolipin (aCL)/anti-β2glycoprotein-I (anti–β2-GPI) IgG/M ≥ 40 U. Stable aPL profile was defined as a clinically meaningful aPL profile in at least two-thirds of follow-up measurements. Generalized linear mixed models with logit link were used for primary objective analysis.ResultsOf 472 patients with clinically meaningful aPL profile at baseline (median follow-up 5.1 yrs), 366/472 (78%) patients had stable aPL profiles over time, 54 (11%) unstable, and 52 (11%) inconclusive. Time did not significantly affect odds of maintaining a clinically meaningful aPL profile at follow-up in univariate (P= 0.906) and multivariable analysis (P= 0.790). Baseline triple aPL positivity decreased (OR 0.25, 95% CI 0.10–0.64,P= 0.004) and isolated LAC test positivity increased (OR 3.3, 95% CI 1.53–7.13,P= 0.002) the odds of an unstable aPL profile over time.ConclusionApproximately 80% of our international cohort patients with clinically meaningful aPL profiles at baseline remain stable at a median follow-up of 5 years; triple aPL-positivity increase the odds of a stable aPL profile. These results will guide future validation studies of stored blood samples through APS ACTION Core Laboratories.

Published
2020

31. Role of microRNAs in the Development of Cardiovascular Disease in Systemic Autoimmune Disorders

Author

Lopez-Pedrera, Chary, Barbarroja, Nuria, Patiño-Trives, Alejandra Mª, Luque-Tévar, Maria, Torres-Granados, Carmen, Aguirre-Zamorano, Mª Angeles, Collantes-Estevez, Eduardo, Pérez-Sánchez, Carlos, [Lopez-Pedrera,C, Barbarroja,N, Patiño-Trives,AM, Luque-Tévar,M, Torres-Granados,C, Aguirre-Zamorano,MA, Collantes-Estevez,E, Pérez-Sánchez,C] Rheumatology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba, Córdoba, Spain., and This study was supported by grants from the Instituto de Salud Carlos III (ref. PI18/00837), cofinanciado por el Fondo Europeo de Desarrollo Regional de la Unión Europea ‘Una manera de hacer Europa’, Spain, the Spanish Inflammatory and Rheumatic Diseases Network (RIER), Instituto de Salud Carlos III (RD16/0012/0015) and the Servicio Andaluz de Salud (PI-0285-2017). C.L-P was supported by a contract from the Spanish Junta de Andalucía (‘Nicolas Monardes’ Program).

Subjects
Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression Regulation [Medical Subject Headings], Síndrome antifosfolípido, Artritis reumatoide, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Trombosis, Phenomena and Processes::Physiological Phenomena::Physiological Processes::Stress, Physiological::Oxidative Stress [Medical Subject Headings], Systemic lupus erythematosus, Antiphospholipid syndrome, Lupus eritematoso sistémico, Diseases::Immune System Diseases::Autoimmune Diseases [Medical Subject Headings], Diseases::Cardiovascular Diseases::Vascular Diseases::Embolism and Thrombosis::Thrombosis [Medical Subject Headings], Chemicals and Drugs::Biological Factors::Biological Markers [Medical Subject Headings], Rheumatoid arthritis, Diseases::Cardiovascular Diseases [Medical Subject Headings], Aterosclerosis, MicroARNs, Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Signal Transduction [Medical Subject Headings], Thrombosis, Diseases::Skin and Connective Tissue Diseases::Connective Tissue Diseases::Lupus Erythematosus, Systemic [Medical Subject Headings], Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::RNA::RNA, Antisense::MicroRNAs [Medical Subject Headings], Atherosclerosis, MicroRNAs, Diseases::Musculoskeletal Diseases::Rheumatic Diseases::Arthritis, Rheumatoid [Medical Subject Headings], Systemic autoimmune diseases, Diseases::Cardiovascular Diseases::Vascular Diseases::Arterial Occlusive Diseases::Arteriosclerosis::Atherosclerosis [Medical Subject Headings], Cardiovascular diasease, Enfermedades cardiovasculares, Diseases::Immune System Diseases::Autoimmune Diseases::Antiphospholipid Syndrome [Medical Subject Headings]
Abstract

Rheumatoid Arthritis (RA), Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are the systemic autoimmune diseases (SADs) most associated with an increased risk of developing cardiovascular (CV) events. Cardiovascular disease (CVD) in SADs results from a complex interaction between traditional CV-risk factors, immune deregulation and disease activity. Oxidative stress, dyslipidemia, endothelial dysfunction, inflammatory/prothrombotic mediators (cytokines/chemokines, adipokines, proteases, adhesion-receptors, NETosis-derived-products, and intracellular-signaling molecules) have been implicated in these vascular pathologies. Genetic and genomic analyses further allowed the identification of signatures explaining the pro-atherothrombotic profiles in RA, SLE and APS. However, gene modulation has left significant gaps in our understanding of CV co-morbidities in SADs. MicroRNAs (miRNAs) are emerging as key post-transcriptional regulators of a suite of signaling pathways and pathophysiological effects. Abnormalities in high number of miRNA and their associated functions have been described in several SADs, suggesting their involvement in the development of atherosclerosis and thrombosis in the setting of RA, SLE and APS. This review focusses on recent insights into the potential role of miRNAs both, as clinical biomarkers of atherosclerosis and thrombosis in SADs, and as therapeutic targets in the regulation of the most influential processes that govern those disorders, highlighting the potential diagnostic and therapeutic properties of miRNAs in the management of CVD. Yes

Published
2020

35. Impaired microRNA processing in neutrophils from rheumatoid arthritis patients confers their pathogenic profile. Modulation by biological therapies

Author

De la Rosa, Ivan Arias, primary, Perez-Sanchez, Carlos, additional, Ruiz-Limon, Patricia, additional, Patiño-Trives, Alejandra, additional, Torres-Granados, Carmen, additional, Jimenez-Gomez, Yolanda, additional, Del Carmen Abalos-Aguilera, Maria, additional, Cecchi, Irene, additional, Ortega, Rafaela, additional, Caracuel, Miguel Angel, additional, Calvo-Gutierrez, Jerusalem, additional, Escudero-Contreras, Alejandro, additional, Collantes-Estevez, Eduardo, additional, Lopez-Pedrera, Chary, additional, and Barbarroja, Nuria, additional

Published
2020
Full Text
View/download PDF

36. Subclinical Cardiovascular Risk Signs in Adults with Juvenile Idiopathic Arthritis in Sustained Remission

Author

Aranda-Valera, Inmaculada Concepcion, primary, Rosa, Iván Arias de la, additional, Roldan-Molina, Rosa, additional, Abalos-Aguilera, Maria del Carmen, additional, Torres-Granados, Carmen, additional, Patiño-Trives, Alejandra, additional, Luque-Tevar, Maria, additional, Ibañez-Costa, Alejandro, additional, Guzman-Ruiz, Rocio, additional, Malagón, Maria del Mar, additional, Escudero-Contreras, Alejandro, additional, Lopez-Pedrera, Chary, additional, Collantes-Estevez, Eduardo, additional, and Barbarroja, Nuria, additional

Published
2020
Full Text
View/download PDF

37. Circulating microRNAs as potential biomarkers for monitoring the response to in vivo treatment with Rituximab in systemic lupus erythematosus patients

Author

Cecchi, Irene, primary, Perez-Sanchez, Carlos, additional, Sciascia, Savino, additional, Radin, Massimo, additional, Arias de la Rosa, Ivan, additional, Barbarroja Puerto, Nuria, additional, Scudeler, Luca, additional, Perez-Sanchez, Laura, additional, Patiño Trives, Alejandra Maria, additional, Aguirre Zamorano, Maria Angeles, additional, Menegatti, Elisa, additional, Roccatello, Dario, additional, and Lopez-Pedrera, Chary, additional

Published
2020
Full Text
View/download PDF

40. Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository.

Author

de Azevedo Lopes, Erivelton, Balbi, Gustavo Guimarães Moreira, Tektonidou, Maria G., Pengo, Vittorio, Sciascia, Savino, Ugarte, Amaia, Belmont, H. Michael, Gerosa, Maria, Fortin, Paul R., Lopez-Pedrera, Chary, Ji, Lanlan, Cohen, Hannah, de Jesús, Guilherme Ramires, Branch, D. Ware, Nalli, Cecilia, Petri, Michelle, Rodriguez, Esther, Kello, Nina, Ríos-Garcés, Roberto, and Knight, Jason S.

Published
2021
Full Text
View/download PDF

41. The frequencies and molecular profiles of CD16+ monocyte subsets in patients with systemic lupus erythematosus, primary antiphospholipid syndrome and antiphospholipid syndrome with lupus, identify specific clinical features of these diseases

Author

Lopez-Pedrera, Chary, Zamorano, Maria Angeles Aguirre, Barbarroja, Nuria, Ruiz-Limon, Patricia, Abalos-Aguilera, Maria Carmen, Jiménez-Gómez, Yolanda, Arias de la Rosa, Ivan, Segui, Pedro, Ortega-Castro, Rafaela, Collantes Estevez, Eduardo, Escudero-Contrera, Alejandro, Le Lann, Lucas, Jamin, Christophe, Maranon, Concepcion, Alarcón-Riquelme, Marta, Pers, Jacques-Olivier, Perez-Sanchez, Carlos, IMIBIC Hospital Universitario Reina Sofia, University of Córdoba [Córdoba], Reina Sofia Hospital-imibic, Cordoba (GC-5/Rheumatology), Biomedical Research Institute (IBIMA), Service of Endocrinology and Nutrition, M ́ alaga Hospital Complex (Virgen de la Victoria), Campus de Teatinos s/n, Universidad de Málaga [Málaga] = University of Málaga [Málaga], Radiology, Reina Sofia Hospital-imibic, Cordoba, Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), LabEX IGO Immunothérapie Grand Ouest, Centre for Genomics and Oncological Reearch (GENYO), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), and Université de Brest (UBO)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018

42. CD16+ monocyte subsets in patients with systemic lupus erythematosus, primary anti-phospholipid syndrome, and anti-phospholipid syndrome with lupus are associated with specific clinical/serological features of these diseases

Author

Perez-Sanchez, C, Barbarroja, Nuria, Aguirre, M.A, Ruiz-Limon, P, Abalos, M.C., Jimenez-Gomez, Y, Arias de la Rosa, I, Segui, P, Le Lann, Lucas, Christophe, Jamin, Alarcón, M., Pers, Jacques-Olivier, Lopez-Pedrera, Chary, Reina Sofia Hospital-imibic, Cordoba (GC-5/Rheumatology), FIMABIS-Virgen de la Victoria Hospital, Malaga, Radiology, Reina Sofia Hospital-imibic, Cordoba, Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Centre for Genomics and Oncological Reearch (GENYO), Reina Sofia University Hospital, IMIBIC, University of Cordoba. Ciber Fisiopatologia Obesidad y Nutricion, Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), and Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018

43. A fine bioinformatical analysis of lymphocyte distribution predicts the diagnosis of primary Sjögren's syndrome among other systemic autoimmune diseases

Author

Simon, Quentin, Rouvière, Bénédicte, Martin, Tifenn, Le Lann, Lucas, Saraux, Alain, Devauchelle-Pensec, Valérie, Marañon, Concepción, Hernandez, Nievas Varela, Dufour, Aleksandra Maria, Chizzolini, Carlo, de Langhe, Ellen, Barbarroja, Nuria, Lopez-Pedrera, Chary, Gerl, Velia, Degroof, Aurélie, Ducreux, Julie, Trombetta, Elena, Li, Tianlu, Alarcón-Riquelme, Marta, Christophe, Jamin, Pers, Jacques-Olivier, Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre for Genomics and Oncological Reearch (GENYO), University of Geneva [Switzerland], Immunology and Allergy, University Hospital and School of Medicine, University Hospitals Leuven [Leuven], Laboratorio de Investigaciones Biomedicas, Fundacion IMABIS. Hospital Virgen de la Victoria, IMIBIC Hospital Universitario Reina Sofia, University of Córdoba [Córdoba], Reina Sofia University Hospital, IMIBIC, University of Cordoba. Ciber Fisiopatologia Obesidad y Nutricion, Department of Rheumatology & Clinical Immunology, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], UCL, Université Catholique de Louvain - Gut Peptide Research Lab, Translational Research Center for Gastrointestinal Disorders, Department of Clinical & Experimental Medicine, Louvain, Belgique, SS/IREC/RUMA Cliniques Universitaires St Luc, Fondazione IRCCS Servizio Di Citometria, Institut d'Investigació Biomèdica de Bellvitge [Barcelone] (IDIBELL), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), and Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018

44. OP0292 THE HELPFUL EIGHT: KEY SPLICING MACHINERY ELEMENTS IN LEUKOCYTE SUBSETS MAY IMPROVE THE TYPIFICATION OF THE DISEASE IN RHEUMATOID ARTHRITIS PATIENTS

Author

Ibañez-Costa, Alejandro, primary, Perez-Sanchez, Carlos, additional, Puerto, Nuria Barbarroja, additional, Río-Moreno, Mercedes del, additional, Pedraza-Arévalo, Sergio, additional, Patiño-Trives, Alejandra M., additional, Luque-Tévar, María, additional, Abalos-Aguilera, Maria del Carmen, additional, Azpilcueta, Pedro Seguí, additional, Laura, Pérez Sánchez, additional, Gutierrez, Jerusalem Calvo, additional, Castro, Rafaela Ortega, additional, Contreras, Alejandro Escudero, additional, Estevez, Eduardo Collantes, additional, Castaño, Justo P, additional, Luque, Raúl M., additional, and Lopez-Pedrera, Chary, additional

Published
2019
Full Text
View/download PDF

45. SAT0124 MOLECULAR CHARACTERIZATION OF THE SERUM PROFILE ASSOCIATED TO THE INCREASED CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS PATIENTS. EFFECTS OF BIOLOGICAL DRUGS.

Author

Perez-Sanchez, Carlos, primary, Puerto, Nuria Barbarroja, additional, Laura, Pérez Sánchez, additional, Ruiz-Limon, Patricia, additional, Martinez, Sara Remuzgo, additional, Ibañez-Costa, Alejandro, additional, Luque-Tevar, Maria, additional, Patiño-Trives, Alejandra M., additional, Rosa, Iván Arias de la, additional, Abalos-Aguilera, Maria del Carmen, additional, Castro, Rafaela Ortega, additional, Contreras, Alejandro Escudero, additional, López-Mejías, Raquel, additional, Ángeles Aguirre-Zamorano, M, additional, Estevez, Eduardo Collantes, additional, González-Gay, Miguel A., additional, and Lopez-Pedrera, Chary, additional

Published
2019
Full Text
View/download PDF

46. SAT0037 INCREASED CARDIOMETABOLIC RISK FACTORS ARE RELATED TO THE ABNORMAL ADIPOCYTOKINE PROFILE AND AUTOIMMUNITY IN RHEUMATOID ARTHRITIS. MODULATION BY TNFALPHA AND IL6R INHIBITORS

Author

Rosa, Iván Arias de la, primary, Abalos-Aguilera, Maria del Carmen, additional, Castro, Rafaela Ortega, additional, Gutierrez, Jerusalem Calvo, additional, Perez-Sanchez, Carlos, additional, Ibañez-Costa, Alejandro, additional, Patiño-Trives, Alejandra, additional, Luque-Tevar, Maria, additional, Estevez, Eduardo Collantes, additional, Lopez-Pedrera, Chary, additional, Contreras, Alejandro Escudero, additional, and Puerto, Nuria Barbarroja, additional

Published
2019
Full Text
View/download PDF

47. THU0225 THE MOLECULAR PROFILING OF MONOCYTES FROM PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME IDENTIFIES SEVERAL NETWORKS RELATED TO THEIR ATHEROTHROMBOTIC STATUS. ROLE OF ANTIPHOSPHOLIPID ANTIBODIES ON MONOCYTE MIRNA SECRETION

Author

Luque-Tévar, María, primary, Laura, Pérez Sánchez, additional, Aguirre, Maria A, additional, Patiño-Trives, Alejandra M., additional, Puerto, Nuria Barbarroja, additional, de la Rosa, Iván Arias, additional, Abalos-Aguilera, Maria del Carmen, additional, Azpilcueta, Pedro Seguí, additional, Villalba, Jose M, additional, Estevez, Eduardo Collantes, additional, Perez-Sanchez, Carlos, additional, and Lopez-Pedrera, Chary, additional

Published
2019
Full Text
View/download PDF

48. AB0388 COMPARATIVE EFFECTIVENESS OF RITUXIMAB, TOCILIZUMAB AND TNFI BIOLOGICS IN RHEUMATOID ARTHRITIS PATIENTS. INFLUENCE OF CLINICAL AND INFLAMMATORY PROFILES

Author

Lopez-Pedrera, Chary, primary, Puerto, Nuria Barbarroja, additional, Perez-Sanchez, Carlos, additional, Ibañez-Costa, Alejandro, additional, Luque-Tevar, Maria, additional, Patiño-Trives, Alejandra, additional, Rosa, Iván Arias de la, additional, Abalos-Aguilera, Maria del Carmen, additional, Castro, Rafaela Ortega, additional, Contreras, Alejandro Escudero, additional, Laura, Pérez Sánchez, additional, Rodríguez-Escalera, Carlos, additional, Ruiz-Montesinos, Dolores, additional, Romero-Barco, Carmen María, additional, Mena-Vázquez, Natalia, additional, Uceda, Julia, additional, Toledo-Coello, Mª Dolores, additional, ángeles Aguirre-Zamorano, M, additional, and Estevez, Eduardo Collantes, additional

Published
2019
Full Text
View/download PDF

49. AB0188 MOLECULAR NETWORKS IN MONOCYTES FROM SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS RELATED TO THEIR PHYSIOPATHOLOGY. MODULATORY EFFECTS OF ANTI-DSDNA ANTIBODIES AND MOLECULAR MECHANISMS UNDERLYING IN VIVOSTATIN TREATMENT

Author

Patiño-Trives, Alejandra M., primary, Laura, Pérez Sánchez, additional, Galindo-Izquierdo, María, additional, Luque-Tévar, María, additional, Ibañez-Costa, Alejandro, additional, Rosa, Iván Arias de la, additional, Abalos-Aguilera, Maria del Carmen, additional, Azpilcueta, Pedro Seguí, additional, Puerto, Nuria Barbarroja, additional, Estevez, Eduardo Collantes, additional, Aguirre, Maria A., additional, Perez-Sanchez, Carlos, additional, and Lopez-Pedrera, Chary, additional

Published
2019
Full Text
View/download PDF

50. SAT0036 IMPACT OF RHEUMATOID ARTHRITIS IN LIVER DAMAGE. INVOLVEMENT OF ANTI-CITRULLINATED PROTEIN ANTIBODIES

Author

Rosa, Iván Arias de la, primary, Torres-Granados, Carmen, additional, Perez-Sanchez, Carlos, additional, Abalos-Aguilera, Maria del Carmen, additional, Patiño-Trives, Alejandra, additional, Luque-Tevar, Maria, additional, Ibañez-Costa, Alejandro, additional, Castro, Rafaela Ortega, additional, Gutierrez, Jerusalem Calvo, additional, Estevez, Eduardo Collantes, additional, Contreras, Alejandro Escudero, additional, Lopez-Pedrera, Chary, additional, and Puerto, Nuria Barbarroja, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results